AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05539755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non surgical debridement of peri-implantitis
Description: The procedure was standardized as follows: the implants' prosthesis was checked for its cleansability, and retrieved when possible. Then, the prosthesis was modified following a previously described elsewhere (de Tapia et al., 2019). After local anaesthesia (articaine 4% and adrenaline 1:100,000), the implant surfaces were cleaned with ultrasonic devices (Newtron P5, Satelec Acteon; Olliergues, France) with the steel alloy H3 dental ultrasonic scaler tip (H3, Satelec Acteon; Olliergues, France), curettage (SyG 7/89 Everdge, Hu-Friedy; Chicago, IL, USA) of the bone defect was performed, and glycine air powder applied submucosally (Air-flow® powder subgingival PERIO, EMS; Nyon, France) with an air-flow piezon device (Air-flow master piezon®, EMS, Nyon; France).~Oral hygiene instructions were given and metronidazole 500 mg every 8 h for 7 days was prescribed. Patients were scheduled at 3 months for supragingival plaque control and supragingival debridement, if needed.
Study NCT05712941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lerociclib
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice a day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study NCT05712941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole 2.5mg
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study NCT05712941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Letrozole 2.5mg
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice daily (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study NCT05712941 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All participants should be treated according to the best-current-practice guidelines and standard of care within each institution or country where the study is conducted.~Participants will be randomized to receive either lerociclib (administered at 150 mg twice day (BID) in combination with letrozole (administered at 2.5 mg once a day (QD), or placebo administered in combination with letrozole (2.5 mg QD).~Participants will also be stratified, using interactive response technology (IRT), by the following randomization strata:~* Endometrial Cancer (EC) tumor staging (Federation Internationale de Gynecologie et d'Obstetrique \[FIGO\] Stage III versus FIGO Stage IV versus recurrent)~* EC tumor grade (Grade 1 versus Grade 2)~* Geographic location (US versus Europe versus Rest of World)
Study NCT04942249 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03911336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group A - test:Tooth extraction and intake of NSAID and a non-NSAID
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 AM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study NCT03911336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B - Control 1: tooth extraction and intake of NSAID and a non-NSAID
Description: Tooth extraction and intake of an NSAID (i.e. Ketoprofen ER 50 mg) at 8 PM and a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8 AM and 2 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study NCT03911336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group C - Control 2: tooth extraction and intake of a Non-Nsaid
Description: Tooth extraction and intake of a non-NSAID (i.e. Acetaminophen / Paracetamol 500 mg) at 8AM, 2 PM and 8 PM for a 3-day period, starting the regime at 2 PM on the day of the extraction.
Study NCT00012935 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Help with decision making on prostate cancer treatment
Study NCT04997746 — intervention group
Intervention type: BEHAVIORAL
Intervention: Multiprofessional educational interventions
Description: Preventive educational interventions
Study NCT04997746 — intervention group
Intervention type: OTHER
Intervention: Measurement of anthropometric measurements
Description: Measurement of height (in meters), weight (in kilograms), knee height, arm circumference and calf circumference (in centimeters)
Study NCT00539799 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisolone
Description: 5 - 7.5 mg/day
Study NCT00539799 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo to prednisolone
Study NCT04681625 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic floor muscle training (PFMT) with suppressive urgency technique
Description: Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day.
Study NCT04681625 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) with suppressive urgency technique
Description: Pelvic floor muscle training with suppressive urgency technique:~1. Education about proper urination training in the period without pathological urgency.~2. Education about conscious urgency suppression through PFMT - suppressive urgency technique.~3. Education on the principle and effect of PFMT.~4. Exercises of varying intensity of pelvic floor muscles in different positions.~5. Exercises to relax the pelvic floor muscles. Exercise 5 times a week for 20-30 minutes a day.
Study NCT04965389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Oral Solution
Description: Specified dose on specified days
Study NCT04965389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]BMS-986177 Solution for Infusion
Description: Specified dose on specified days
Study NCT04965389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177 Spray-dried Dispersion Capsules
Description: Specified dose on specified days
Study NCT06090682 — intervention group
Intervention type: DEVICE
Intervention: Deep Brain Stimulation(DBS) and Transcranial Magnetic Stimulation(TMS)
Description: We observed the changes in cognitive function of patients before and after different brain stimulation treatments, and further compared the effects of different brain stimulation treatments on cognitive function of PD patients and the related mechanisms according to whether DBS surgery was performed or TMS therapy was given only according to the surgical indications.
Study NCT05356182 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Control diet consisting of 20% protein, intervention diet consisting of 10% protein
Study NCT05471635 — intervention group
Intervention type: BIOLOGICAL
Intervention: COVID-19 Vaccine
Description: All COVID-19 vaccines approved by national or international regulatory agency, despite the vaccine technology, manufacturer, and regulatory agency that granted marketing authorization.
Study NCT04880538 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic procedure
Description: Endoscopic biopsy of one or more of the following: esophagus, stomach, small bowel, colon, or rectum as part of patient clinical care. Biopsies will be performed during endoscopy or colonoscopy and will be transported to the research laboratory for evaluation.
Study NCT04996680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood Flow Restriction (by using smart-cuff pro devices, acting as pressurized tourniquet) combined low load strengh training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with optimal pressurized blood flow restriction
Study NCT04996680 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardised low load strength training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises
Study NCT04996680 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-BFR (by using smart-cuff pro devices, acting as pressurized tourniquet) combined with low load strength training
Description: This group will undergo standard, traditional low load strength training consisting of calf, thigh, glute and core exercises, combined with blood flow restriction, but pressurized so the occlusion cuff has no significant effect on the lower limb blood flow.
Study NCT05658406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 15 mL/kg/hour Ringer's lactate intraoperative
Study NCT05658406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 10 mL/kg/hour Ringer's lactate intraoperative .
Study NCT05658406 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: infusion of 6 mL/kg/hour Ringer's lactate intraoperative .
Study NCT05658406 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal Saline
Description: standard fluid management: 4 ml for 1st 10 kg, 2 ml for the next 10 kg , 1 ml rest of body weight
Study NCT04650958 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
Study NCT04650958 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Deep brain stimulation
Description: Deep brain stimulation (DBS) has been in use to treat patients with movement disorders since 1989, with many thousands of publications showing its effectiveness. DBS for dystonia received the US FDA mark in 2003 and China FDA mark in 2016. In this study, the DBS system devices are manufactured and donated by SceneRay (Suzhou, China). The Stimulator System is implanted by a qualified neurosurgeon and consists of three implantable components: the leads, the extension wires and the neurostimulator. The DBS programming will start within 1 week after the surgery completed.
Study NCT05970744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/Flu-01E low dose
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (7.7 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
Study NCT05970744 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV/Flu-01E high dose
Description: Participants will receive single intranasal injection of A/H1N1pdm09 recombinant attenuated influenza vector (8.4 lg EID50) with modified NS gene coding for the F antigen of respiratory syncytial virus
Study NCT05970744 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive single intranasal injection of Placebo
Study NCT06170372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 ppm Nitric Oxide
Description: NO will be supplemented at 200-ppm concentration 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Study NCT06170372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sham treatment
Description: Oxygen-air mixture without NO 3 times a day for 30 min until the pneumonia resolves, but no more than 7 days
Study NCT05608317 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ALLEVYN Non-Adhesive
Description: ALLEVYN Non-Adhesive combines patient comfort with the tri-layer fluid management system that enables moist wound healing. It utilizes a unique triple action technology that manages fluid to maintain optimal moist wound healing conditions. It is ideal for fragile and sensitive skin due to its non-adherent wound contact layer and soft and conformable construction.~ALLEVYN Non-Adhesive consists of the following layers:~* Breathable top film~* Highly absorbent foam core~* Non-adhesive wound contact layer
Study NCT05790447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin
Description: loading dose with thymalfasin based on the amounts of T lymphocyte
Study NCT05790447 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: hypofractionated radiotherapy/SBRT
Study NCT05790447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 inhibitor
Description: The PD-1/PD-L1 inhibitors are used within one week after radiotherapy
Study NCT05790447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: subcutaneous injection daily for 7 consecutive days
Study NCT04812327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BD Veritor Plus System for Rapid Detection of SARS CoV-2
Description: Nasal Sawb for the conduct of the Veritor Antigen Test
Study NCT04812327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: rt-PCR
Description: Nasopharyngeal Swab for the conduct of a rt-PCR
Study NCT05425433 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tailored serial casting intercention
Description: Every participant will undergo 1 week of usual care for the affected joint according to the OT's prescription (static progressive, dynamic or serial static) combined with stretching, moisturizers, pressure therapy, or thermal modalities. After the one week of splinting, if the PROM of the targeted joint does not improve, the participant will start serial casting (Monday to Friday). Patients will have a cast applied on Monday morning and worn for 24hrs/day or for 48hrs according to the OTs and treating physician's decision (rationale documented).The OT will decide how many weeks the participant will be wearing casts and the rationale to stop this treatment will be documented. When the treatment is stopped, patients will be encouraged to wear a maintenance splint for the following 2 weeks.
Study NCT04920617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DPX-Survivac
Description: SC injection on D7 and D28, then every 8 weeks
Study NCT04920617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion every 3 weeks
Study NCT04920617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPA
Description: 50 mg twice daily, week on then week off
Study NCT04812327 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: viral culture
Description: Nasopharyngeal Swab for the conduct of viral culture
Study NCT06554860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular Blackburn stabilization plus exercise
Description: scapular Blackburn stabilization
Study NCT06554860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF plus Exercise
Description: PNF plus Exercise
Study NCT06554860 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: exercise only
Description: Exercise only
Study NCT05752513 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Late bladder dissection
Description: The bladder dissection is reserved as the last step of the cesarean hysterectomy with excellent dissection of the ureteric course till the ureteric tunnel to reduce the incidence of inadvertent ureteric clamping during uterine vessel ligating and transection
Study NCT05752513 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: early bladder dissection
Description: The bladder dissection is early as in classic cesarean hysterectomy
Study NCT05717751 — intervention group
Intervention type: PROCEDURE
Intervention: surgical staging
Description: para-aortic lymphadenectomy from the inferior mesenteric artery cranially to the aorta caudally via laparoscopy or laparotomy
Study NCT05483335 — intervention group
Intervention type: OTHER
Intervention: No intervention but assessing for burnout syndrome in all group
Description: Using Maslach Burnout inventory to assess the presence of burnout and a self reporting questionnaire to identify possible stressors or associations
Study NCT06022367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Turn Activation Technique
Description: Participant sat upright with head turned to the side through 45 degrees. They are presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
Study NCT06022367 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Head Raise Activation Technique
Description: Participant assumes caloric test position (30 degrees from horizontal) with head raised. Participant is presented with an auditory stimulus delivered using insert earphones and their cVEMP response is recorded using skin electrodes.
Study NCT06598293 — intervention group
Intervention type: BEHAVIORAL
Intervention: PRO-CTCAE, Pain NRS
Description: The Common Terminology Criteria for Adverse Events (PRO-CTCAE) is a PROM developed to systematically and objectively reflect patients' experiences and perceptions of therapeutic drugs in toxicity evaluation and adverse event reporting. PRO-CTCAE can be used to monitor patients' symptoms and side effects, support therapeutic decision-making, facilitate communication among medical staff, implement patient-centred care, and screen for health conditions.
Study NCT06616454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group - Time restricted feeding
Description: Participants will be applied with an ad libitum nutrition plan between 10:00-18:00.
Study NCT06689722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: chiropractic
Description: Chiropractic practice was applied using the diversified technique, which is one of the types of chiropractic techniques.
Study NCT06689722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham
Description: The patient was asked if he/she had any pain or other complaints during the trial mobilization. High-velocity, low-amplitude impulses were applied to the inferior and lateral directions for patients who did not describe any complaints.
Study NCT06689722 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa
Study NCT06689722 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa
Study NCT06689722 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: ergonomics
Description: Ergonomics training will be given to each of the control group participants individually. The content of this training will include what is ergonomics, the purpose of ergonomics, musculoskeletal diseases in employees, work-related musculoskeletal risk fa
Study NCT05336305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Polydextrose
Description: Administration of 3g polydextrose per day, for 2 months
Study NCT05619393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobilie Bi-planar X-ray Imaging system
Description: on the Mobilie Bi-planar X-ray Imaging system, images are acquired for three movements: walking, downhill walking, and squat
Study NCT05336305 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Administration of 3g polydextrose per day, for 2 months